The preliminary results of a clinical trial suggest a new treatment for Covid-19 dramatically reduces the number of patients needing intensive care, according to the UK company that developed it. The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection. The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune response. The initial findings suggest the treatment cut the odds of a Covid-19 patient in hospital developing severe disease – such as requiring ventilation – by 79%.
Coronavirus: Protein treatment trial ‘a breakthrough’ – BBC News
